CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced a non-exclusive, royalty-bearing license agreement to its ARGENT™ cell-signaling regulation technology with Bellicum Pharmaceuticals, Inc. to develop and commercialize new cancer therapies. ARIAD will have an equity stake in Bellicum and will receive additional payments based on certain development, regulatory and commercial milestones achieved by the company. Products in this partnership will use ARIAD’s small-molecule dimerizer drug, AP1903, which already has successfully completed a Phase 1 clinical trial.
